Recently, a significant study authored by Safar Center researchers Dr. Bob Clark, Dr. Philip Empey, and others, was published in the Journal PLOS One, titled “Phase I Randomized Clinical Trial of N-acetylcysteine in Combination with an Adjuvant Probenecid for Treatment of Severe Traumatic Brain Injury in Children.”

The study examined the effects of the administration of the antioxidant N-acetylcysteine (NAC) and the synergistic adjuvant probenecid in children with severe TBI. Probenecid was shown to facilitate accumulation of NAC in brain, enhancing the penetration of NAC across the blood-brain barrier. The study builds on pre-clinical research carried out in collaboration between the Safar Center and the School of Pharmacy, and represents a groundbreaking first approach to combination therapy in the field of TBI.

You can read the open-access article here ›